Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Cytokinetics Incorporated (CYTK) stocks in Canada

Learn how to easily invest in Cytokinetics Incorporated stocks.

Cytokinetics Incorporated is a biotechnology business based in the US. Cytokinetics Incorporated stocks (CYTK.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $19.73 – a decrease of 3.56% over the previous week. Cytokinetics Incorporated employs 184 staff and has a trailing 12-month revenue of around $21.6 million.

How to buy shares in Cytokinetics Incorporated

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CYTK – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Cytokinetics Incorporated stock price (NASDAQ:CYTK)

Use our graph to track the performance of CYTK stocks over time.

Cytokinetics Incorporated shares at a glance

Information last updated 2022-01-17.
Latest market close$31.71
52-week range$17.72 - $47.90
50-day moving average $39.39
200-day moving average $30.91
Wall St. target price$55.83
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.11

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Cytokinetics Incorporated stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Cytokinetics Incorporated price performance over time

Historical closes compared with the close of $31.71 from 2022-01-19

1 week (2022-01-13) -3.56%
1 month (2021-12-20) -19.72%
3 months (2021-10-20) -11.25%
6 months (2021-07-20) 8.67%
1 year (2021-01-20) 58.71%
2 years (2020-01-17) 161.20%
3 years (2019-01-18) 362.92%
5 years (2017-01-20) 199.15%

Cytokinetics Incorporated financials

Revenue TTM $21.6 million
Gross profit TTM $-41,123,000
Return on assets TTM -19.3%
Return on equity TTM -114.73%
Profit margin 0%
Book value $2.97
Market capitalisation $2.8 billion

TTM: trailing 12 months

Cytokinetics Incorporated share dividends

We're not expecting Cytokinetics Incorporated to pay a dividend over the next 12 months.

Have Cytokinetics Incorporated's shares ever split?

Cytokinetics Incorporated's shares were split on a 1:6 basis on 24 June 2013. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cytokinetics Incorporated shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Cytokinetics Incorporated shares which in turn could have impacted Cytokinetics Incorporated's share price.

Cytokinetics Incorporated share price volatility

Over the last 12 months, Cytokinetics Incorporated's shares have ranged in value from as little as $17.72 up to $47.9. A popular way to gauge a stock's volatility is its "beta".

CYTK.US volatility(beta: 1.24)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cytokinetics Incorporated's is 1.2397. This would suggest that Cytokinetics Incorporated's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Cytokinetics Incorporated overview

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, and in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274 (CK-274), a novel cardiac myosin inhibitor, which is in Phase II clinical trial for the potential treatment of hypertrophic cardiomyopathy; CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and CK-3772271 (CK-271), a novel cardiac myosin inhibitor that is in Phase I clinical trial. The company has a strategic alliance with Astellas Pharma Inc. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Stocks similar to Cytokinetics Incorporated

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site